◆ mixed
Impact
PhasePhase 2
Time to marketUnknown — MT-601 is in Phase 2 for lymphoma (APOLLO study) and preparing a Phase 1 pancreatic cancer study (expected Q1 2027). A registrational trial has not yet begun. At minimum 3-5 years away from potential approval, if ever.
MT-601 Updated Oct 24
What to watch
Watch for the Phase 1 pancreatic cancer study initiation in Q1 2027 and the upcoming Q3 2026 earnings (Nov 11). The critical near-term risk is the company's cash runway, with ~$17M at year-end 2025 and a $12M+ annual burn, MRKR likely needs to raise capital within months, which would dilute existing shareholders. The massive analyst price target spread ($5.60-$10 vs $0.96 stock) suggests genuine clinical promise but extreme execution risk at current funding levels.
Bull case
- MT-601 showed compelling early efficacy: 66% objective response rate (8/12 evaluable patients) including 50% complete responses in relapsed/refractory non-Hodgkin lymphoma from the APOLLO study, and 78% ORR in Hodgkin lymphoma.
- Pancreatic cancer data published in Nature Medicine showed 84.6% disease control rate and 14.1-month median overall survival when MT-601 was combined with chemotherapy in a prior Baylor investigator-sponsored study.
- FDA awarded a competitive $2.6M Orphan Products Clinical Trials Grant (only 6 of 66 applications funded in FY2026) for the MT-601 pancreatic cancer program, a strong external validation of the scientific rationale.
Bear case
- Cash runway is tight, $17M at year-end 2025 funded only through Q4 2026, and with a ~$12M annual operating burn the company likely needs to raise capital imminently. Stock is already near its 52-week low of $0.84, and a proposed 4.3x increase in authorized shares (from 30M to 130M) signals significant shareholder dilution ahead.
- The clinical data comes from very small cohorts (8-12 patients per indication). Historical 66% ORR in the APOLLO lymphoma study and 84.6% disease control rate in pancreatic cancer may not replicate in larger, controlled trials.
- Pancreatic cancer is an extremely difficult indication with a long history of failed therapies. The Phase 1 study has not yet started enrollment (expected Q1 2027) and faces high technical risk.